Clinical Trial Update: A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) [Phase 3]

View source ↗

Summary

Phase 3 ROCKET-IGNITE trial evaluating Rocatinlimab for moderate-to-severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED